Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.127
Sell
RSI(14)
28.702
Sell
STOCH(KDJ)(9,3,3)
9.355
Oversold
ATR(14)
0.144
High Vlolatility
CCI(14)
-158.209
Sell
Williams %R
89.313
Oversold
TRIX(12,20)
-0.532
Sell
StochRSI(14)
0.000
Oversold
Lexaria Bioscience Corp
LEXX0.583USD
-0.103-14.96%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
11.40MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Lexaria Bioscience Corp
Currency: USD Updated: 2025-12-19Key Insights
Lexaria Bioscience Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 101/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.33.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lexaria Bioscience Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
5.333
Target Price
+389.30%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Lexaria Bioscience Corp Highlights
StrengthsRisks
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 212.07% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 705.92K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 705.92K.
Overvalued
The company’s latest PE is -0.88, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.42M shares, increasing 7.37% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 258.82K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Lexaria Bioscience Corp is 7.26, ranking 122/158 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 174.00K, representing a year-over-year increase of 107.14%, while its net profit experienced a year-over-year increase of 23.39%.
Score
Financials
7.31
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.47
Operational Efficiency
2.86
Growth Potential
10.00
Shareholder Returns
7.65
Lexaria Bioscience Corp's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Lexaria Bioscience Corp is 6.63, ranking 118/158 in the Pharmaceuticals industry. Its current P/E ratio is -0.88, which is -32.59% below the recent high of -0.59 and -953.12% above the recent low of -9.28.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 101/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of Lexaria Bioscience Corp is 8.00, ranking 56/158 in the Pharmaceuticals industry. The average price target for Lexaria Bioscience Corp is 6.00, with a high of 6.00 and a low of 4.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
5.333
Target Price
+389.30%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Lexaria Bioscience Corp
LEXX
2
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Lexaria Bioscience Corp is 6.69, ranking 110/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.19 and the support level at 0.23, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.736
Sell
MA10
0.963
Sell
MA20
1.022
Sell
MA50
1.005
Sell
MA100
0.994
Sell
MA200
1.080
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Lexaria Bioscience Corp is 3.00, ranking 92/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 10.89%, representing a quarter-over-quarter decrease of 21.23%. The largest institutional shareholder is The Vanguard, holding a total of 258.82K shares, representing 1.04% of shares outstanding, with 42.80% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Bunka (Christopher A)
Boos (Wayne W)
Invenomic Capital Management LP
Geode Capital Management, L.L.C.
TD Securities, Inc.
Christopher (Richard C)
Docherty (John Martin)
State Street Investment Management (US)
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Lexaria Bioscience Corp is 1.63, ranking 148/158 in the Pharmaceuticals industry. The company's beta value is 0.67. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.67
VaR
+7.99%
240-Day Maximum Drawdown
+73.99%
240-Day Volatility
+112.27%
Return
Best Daily Return
60 days
+13.26%
120 days
+32.44%
5 years
+35.29%
Worst Daily Return
60 days
-33.58%
120 days
-33.58%
5 years
-33.58%
Sharpe Ratio
60 days
-2.18
120 days
-0.09
5 years
-0.09
Risk Assessment
Maximum Drawdown
240 days
+73.99%
3 years
+90.68%
5 years
+93.10%
Return-to-Drawdown Ratio
240 days
-0.99
3 years
-0.29
5 years
-0.20
Skewness
240 days
-0.62
3 years
+0.27
5 years
+0.39
Volatility
Realised Volatility
240 days
+112.27%
5 years
+110.84%
Standardised True Range
240 days
+18.73%
5 years
+40.30%
Downside Risk-Adjusted Return
120 days
-9.79%
240 days
-9.79%
Maximum Daily Upside Volatility
60 days
+101.61%
Maximum Daily Downside Volatility
60 days
+116.41%
Liquidity
Average Turnover Rate
60 days
+0.98%
120 days
+0.77%
5 years
--
Turnover Deviation
20 days
-30.29%
60 days
-34.65%
120 days
-48.99%
Peer Comparison
Pharmaceuticals
Lexaria Bioscience Corp
LEXX
6.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Lexaria Bioscience Corp?
The TradingKey Stock Score provides a comprehensive assessment of Lexaria Bioscience Corp based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Lexaria Bioscience Corp’s performance and outlook.
How do we generate the financial health score of Lexaria Bioscience Corp?
To generate the financial health score of Lexaria Bioscience Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Lexaria Bioscience Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Lexaria Bioscience Corp.
How do we generate the company valuation score of Lexaria Bioscience Corp?
To generate the company valuation score of Lexaria Bioscience Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Lexaria Bioscience Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Lexaria Bioscience Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Lexaria Bioscience Corp.
How do we generate the earnings forecast score of Lexaria Bioscience Corp?
To calculate the earnings forecast score of Lexaria Bioscience Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Lexaria Bioscience Corp’s future.
How do we generate the price momentum score of Lexaria Bioscience Corp?
When generating the price momentum score for Lexaria Bioscience Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Lexaria Bioscience Corp’s prices. A higher score indicates a more stable short-term price trend for Lexaria Bioscience Corp.
How do we generate the institutional confidence score of Lexaria Bioscience Corp?
To generate the institutional confidence score of Lexaria Bioscience Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Lexaria Bioscience Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Lexaria Bioscience Corp.
How do we generate the risk management score of Lexaria Bioscience Corp?
To assess the risk management score of Lexaria Bioscience Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Lexaria Bioscience Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Lexaria Bioscience Corp.
